Caribou Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M |
| Research and development | $109.4M | $130.2M | $112.1M | $82.2M | $52.3M |
| Operating expenses | $159.5M | $176.6M | $150.5M | $120.2M | $76.6M |
| Operating income | -$148.3M | -$166.6M | -$116.1M | -$106.4M | -$67.0M |
| Interest expense | — | — | — | — | $8,000 |
| Pretax income | -$148.7M | -$149.1M | -$101.9M | -$99.4M | -$66.6M |
| Income tax expense | -$550,000 | -$9,000 | $193,000 | $70,000 | $321,000 |
| Net income | -$148.1M | -$149.1M | -$102.1M | -$99.4M | -$66.9M |
| Balance Sheet | |||||
| Cash and equivalents | $12.4M | $16.3M | $51.2M | $58.3M | $240.4M |
| Current assets | $145.2M | $219.4M | $338.8M | $260.2M | $391.2M |
| Total assets | $175.4M | $313.3M | $432.2M | $373.8M | $442.4M |
| Current liabilities | $25.4M | $30.7M | $28.3M | $28.1M | $25.8M |
| Total liabilities | $53.2M | $60.4M | $63.8M | $72.9M | $54.5M |
| Stockholders' equity | $122.2M | $253.0M | $368.4M | $300.9M | $387.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$111.0M | -$138.2M | -$93.3M | -$91.0M | -$32.5M |
| Depreciation and amortization | $3.6M | $3.9M | $3.5M | $1.6M | $984,000 |
| Stock-based compensation | $12.7M | $16.7M | $13.8M | $11.7M | $3.4M |
| Capital expenditure | $1.4M | $4.9M | $11.6M | $6.5M | $2.1M |
| Free cash flow | -$112.4M | -$143.1M | -$104.9M | -$97.4M | -$34.6M |
| Impairments | $12.2M | $0 | — | — | — |
Shares outstanding 99.2M · Free float 87.7%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.